NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo

Loading news article.

NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo | WAPE

NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo

Article summary

Related companies

Comments —